NHS to offer second dose of MenB vaccine after Kent outbreak

NHS to Offer Second Dose of MenB Vaccine Following Kent Outbreak

Following a meningitis B outbreak that claimed two lives and infected 19 others in Kent, the NHS has announced plans to provide a second dose of the vaccine to nearly 12,000 individuals who received the first round of immunizations. The initiative, which involves administering the second dose at least four weeks after the initial one, will commence next week. Eligible recipients include university students, school pupils, and others who may have been exposed to the bacteria.

Outbreak Details

The outbreak, which occurred in late September, has prompted a targeted vaccination campaign. NHS Kent and Medway confirmed that clinics will operate in Canterbury, Faversham, and Ashford, with online booking systems available for scheduling appointments. A 21-year-old university student and sixth form pupil Juliette Kenny were among those who succumbed to the disease, while many others required inpatient care.

Health Secretary Wes Streeting labeled the outbreak as “unprecedented” due to its rapid spread. The UK Health Security Agency (UKHSA) also declared a national incident to facilitate the distribution of antibiotics and other resources.

Vaccination Rollout

The targeted program initially focused on students residing in university halls in Kent and those who frequented a nightclub linked to the outbreak. Subsequently, the scope was broadened to include sixth form students at schools or colleges where cases had been confirmed or suspected. Preventative antibiotics were provided to a larger group, with long lines forming at the University of Kent over several days.

Background and Context

A routine MenB vaccination program was introduced in the UK in 2015, primarily for infants and young children. At that time, UK health advisers determined that a widespread catch-up campaign for teenagers was not cost-effective. Teenagers are now offered the MenACWY vaccine, which covers four meningitis-causing bacteria but excludes MenB. The recent incident has led to a reassessment of this decision by independent experts on the Joint Committee on Vaccination and Immunisation (JCVI).